Back to top
more

Neogen (NEOG)

(Delayed Data from NSDQ)

$14.44 USD

14.44
1,190,769

+0.16 (1.12%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neogen (NEOG) to Report Q4 Results: What You Should Expect

by Zacks Equity Research

Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEOGEN (NEOG) Enhances Aquaculture Genotyping With New Pact

by Zacks Equity Research

NEOGEN (NEOG) together with CAT can enable members of the aquaculture sector to make more informed breeding decisions.

NEOGEN's (NEOG) Soleris Test to Serve the Cannabis Industry

by Zacks Equity Research

NEOGEN's (NEOG) Soleris Direct Yeast and Mold test is approved by the AOAC Institute to identify yeasts and molds in dried cannabis flower.

    Neogen (NEOG) Up 13.1% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

    Neogen (NEOG) Hits New 52-Week High: What's Driving It?

    by Zacks Equity Research

    Strong performance in both its Animal Safety and Food Safety segments during the fiscal third quarter pushes Neogen (NEOG) to a 52-week high.

      NEOGEN's (NEOG) Earnings Miss Estimates in Q3, Margins Up

      by Zacks Equity Research

      NEOGEN's (NEOG) third-quarter fiscal 2021 revenues increase 16.9% year over year, driven by strong segmental growth and robust international business.

      Neogen (NEOG) Q3 Earnings Miss Estimates

      by Zacks Equity Research

      Neogen (NEOG) delivered earnings and revenue surprises of -7.41% and 9.00%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?

      Neogen (NEOG) Earnings Expected to Grow: What to Know Ahead of Q3 Release

      by Zacks Equity Research

      Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      NEOGEN's (NEOG) New Test to Identify Coronavirus in Wastewater

      by Zacks Equity Research

      Launch of NEOGEN's (NEOG) latest test, which marks its entry into wastewater testing, is expected to become a key tool to combat COVID-19.

      Neogen (NEOG) Up 5.1% Since Last Earnings Report: Can It Continue?

      by Zacks Equity Research

      Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      NEOGEN's (NEOG) New Test to Aid in Detecting Cancer-Causing Toxin

      by Zacks Equity Research

      NEOGEN's (NEOG) latest test is expected to simplify the process of milk testing as well as detecting lower levels of the carcinogenic metabolite Aflatoxin M1.

      Neogen (NEOG) Launches Dairy Toxin Detection Test Reveal Q+

      by Zacks Equity Research

      Neogen's (NEOG) new test can detect cancer causing aflatoxin M1 in milk within a range of 150-600 parts per trillion (ppt).

      New Strong Sell Stocks for January 12th

      by Zacks Equity Research

      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

      NEOGEN (NEOG) Fortifies Global Position via Megazyme Buyout

      by Zacks Equity Research

      NEOGEN's (NEOG) buyout of Megazyme is expected to strengthen its Food Safety business worldwide.

      NEOGEN (NEOG) Q2 Earnings and Revenues Fall Shy of Estimates

      by Zacks Equity Research

      NEOGEN's (NEOG) segmental revenues improve for fiscal second quarter on strong sales of cleaners and disinfectants.

      Here's Why You Should Hold onto NEOGEN (NEOG) Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

      Neogen (NEOG) Q2 Earnings and Revenues Lag Estimates

      by Zacks Equity Research

      Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and -0.39%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?

      NEOGEN (NEOG) Launches DNA Screening Tool for Canine Care

      by Zacks Equity Research

      NEOGEN's (NEOG) latest DNA screening tool is expected to aid veterinarians to provide healthy lifestyle recommendations for a longer and happier life for each pet and its family.

      NEOGEN (NEOG), Transnetyx Partner to Advance Mouse Genotyping

      by Zacks Equity Research

      NEOGEN (NEOG) aims to better serve the biomedical research community with a comprehensive and affordable solution for the genetic background testing of their mouse models via the partnership.

      Neogen (NEOG) Down 5.8% Since Last Earnings Report: Can It Rebound?

      by Zacks Equity Research

      Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?

      by Zacks Equity Research

      Sector ETF report for PSCH

      Here's Why You Should Add NEOGEN (NEOG) to Your Portfolio Now

      by Zacks Equity Research

      Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

      Is Neogen (NEOG) a Solid Growth Stock? 3 Reasons to Think " Yes "

      by Zacks Equity Research

      Neogen (NEOG) possesses solid growth attributes, which could help it handily outperform the market.

      Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?

      by Zacks Equity Research

      Sector ETF report for PSCH